North Carolina 2017-2018 Session Status: In Committee Bipartisan · 1 R · 1 D cosponsors

SB 152 — NC Cancer Treatment Fairness.

Last action — Passed 1st Reading

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed Senate
  4. 4
    Passed House
  5. 5
    To Executive
  6. 6
    Enacted

This bill died with 2017-2018 Session. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.

This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.

Bill Text

What changed in the latest version

18 added · 18 removed

Plain-language change summary

The updated version of Senate Bill 152 clarifies that any increases in out-of-pocket costs for anticancer drugs must also apply to similar medical or pharmaceutical benefits. This change is important because it ensures that patients are not burdened with higher costs for cancer treatments while comparable treatments remain unaffected. The bill aims to create fairer insurance practices for those undergoing cancer treatment, promoting better access to necessary medications.

→
Previous
Latest
FILED SENATE GENERAL ASSEMBLY OF NORTH CAROLINA Feb 28, 2017 S.B.
GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2017 S 1 SENATE BILL 152* Short Title:
152 SESSION 2017 PRINCIPAL CLERK S D SENATE BILL DRS45110-MR-22C* (01/23) Short Title:
Senators Hise, Tillman, and Brock (Primary Sponsors).
Senators Hise, Tillman, Brock (Primary Sponsors);
Ballard, Bryant, Cook, Dunn, Horner, Krawiec, Newton, Rabin, Randleman, and Smith-Ingram.
A BILL TO BE ENTITLED AN ACT RELATING TO HEALTH BENEFIT PLAN COVERAGE FOR ORALLY ADMINISTERED ANTICANCER DRUGS.
Rules and Operations of the Senate March 1, 2017 A BILL TO BE ENTITLED AN ACT RELATING TO HEALTH BENEFIT PLAN COVERAGE FOR ORALLY ADMINISTERED ANTICANCER DRUGS.
(c) A policy, contract, or plan provider shall not achieve compliance with this section by reclassifying anticancer drugs or by increasing patient cost-sharing, including any coinsurance, co-payment, deductible, or other out-of-pocket expenses imposed on anticancer drugs.
(c) A policy, contract, or plan provider shall not achieve compliance with this section by reclassifying anticancer drugs or by increasing patient cost-sharing, including any coinsurance, *S152-v-1* General Assembly Of North Carolina Session 2017 co-payment, deductible, or other out-of-pocket expenses imposed on anticancer drugs.
Any policy, *DRS45110-MR-22C* General Assembly Of North Carolina Session 2017 contract, or plan change that otherwise increases an out-of-pocket expense applied to anticancer drugs must also be applied to the majority of comparable medical or pharmaceutical benefits covered by the policy, contract, or plan." SECTION 2.
Any policy, contract, or plan change that otherwise increases an out-of-pocket expense applied to anticancer drugs must also be applied to the majority of comparable medical or pharmaceutical benefits covered by the policy, contract, or plan." SECTION 2.
Page 2 DRS45110-MR-22C* [v.2] (01/17)
Page 2 Senate Bill 152*-First Edition
⬇ Download PDF
View plain text versions (2)

Action History

  1. Passed 1st Reading

  2. Ref To Com On Rules and Operations of the Senate

  3. Filed

Sponsors

  • Tillman · Primary
  • Randleman · Cosponsor
  • Rabin · Cosponsor
  • Krawiec · Cosponsor
  • Horner · Cosponsor
  • Ralph Hise · Primary
  • Dunn · Cosponsor
  • Cook · Cosponsor
  • Bryant · Cosponsor
  • Brock · Cosponsor
  • Ballard · Cosponsor
  • Newton · Cosponsor
  • Kandie D. Smith · Cosponsor

Sponsorship breakdown

Export CSV (upgrade) →

2 sponsors · 11 co-sponsors · 166 not signed on

Sponsors (2)

Co-sponsors (11)

  • Randleman
  • Rabin
  • Krawiec
  • Horner
  • Dunn
  • Cook
  • Bryant
  • Brock
  • Ballard
  • Newton
  • Kandie D. Smith Democratic

Not signed on (166)

166 members have not signed on to this bill.

Show all 166 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

Who sponsors SB 152?
SB 152 is sponsored by Tillman, Randleman, Rabin, Krawiec, Horner, Ralph Hise (Republican), Dunn, Cook, Bryant, Brock, Ballard, Newton, and Kandie D. Smith (Democratic).
What is the current status of SB 152?
This bill died with 2017-2018 Session. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
Where can I track SB 152?
Track SB 152 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on SB 152

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of SB 152

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →